- Home
- SAND vs WGS Comparison
SAND vs WGS Comparison
Compare SAND & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAND
- WGS
- Stock Information
- Founded
- SAND 2007
- WGS 2017
- Country
- SAND Canada
- WGS United States
- Employees
- SAND N/A
- WGS N/A
- Industry
- SAND
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- SAND
- WGS Technology
- Exchange
- SAND NYSE
- WGS Nasdaq
- Market Cap
- SAND 1.9B
- WGS 2.0B
- IPO Year
- SAND N/A
- WGS N/A
- Fundamental
- Price
- SAND $5.98
- WGS $95.83
- Analyst Decision
- SAND Buy
- WGS Strong Buy
- Analyst Count
- SAND 3
- WGS 5
- Target Price
- SAND $9.17
- WGS $82.60
- AVG Volume (30 Days)
- SAND 6.2M
- WGS 1.5M
- Earning Date
- SAND 02-18-2025
- WGS 02-18-2025
- Dividend Yield
- SAND 1.05%
- WGS N/A
- EPS Growth
- SAND N/A
- WGS N/A
- EPS
- SAND 0.05
- WGS N/A
- Revenue
- SAND $176,283,000.00
- WGS $305,450,000.00
- Revenue This Year
- SAND N/A
- WGS $44.70
- Revenue Next Year
- SAND $20.70
- WGS $16.73
- P/E Ratio
- SAND $124.27
- WGS N/A
- Revenue Growth
- SAND N/A
- WGS 50.79
- 52 Week Low
- SAND $3.99
- WGS $7.16
- 52 Week High
- SAND $6.67
- WGS $115.60
- Technical
- Relative Strength Index (RSI)
- SAND 47.16
- WGS 59.30
- Support Level
- SAND $5.62
- WGS $65.10
- Resistance Level
- SAND $6.53
- WGS $115.60
- Average True Range (ATR)
- SAND 0.21
- WGS 9.03
- MACD
- SAND -0.04
- WGS 3.96
- Stochastic Oscillator
- SAND 34.29
- WGS 65.30
About SAND SANDSTORM GOLD LIMITED
Sandstorm Gold Ltd provides financing to companies engaged in gold mining through the gold stream and royalty. Geographically, the company has operational footprints in North America, South & Central America, Africa, and Asia & Australia. The firm's royalties include Hod Maden, Santa Elena, Chapada, Platreef, Greenstone, and Cerro Moro.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.